# US 5,352,688 A · Methods for the treatment of bradyphrenia in parkinson's disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,688 A
- Document ID: US5352688A
- Status: Granted
- Kind: A
- Application number: 07/954,258
- Filed: 1992-09-30
- Granted: 1994-10-04
- Earliest claimed: 1991-02-15
- Assignees: Mount Sinai School of Medicine of the City University of New York
- Inventors: Ram Kaminski
- Web page: https://patentgrep.com/patent/US5352688A

## CPC

- A61K 31/415: 1,2-Diazoles
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/425: Thiazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/54: having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Neuropsychiatric symptoms of Parkinson's Disease and particularly the symptoms of apathy-amotivation and mental slowing can be ameliorated by treating a patient suffering from Parkinson's Disease with a histamine H.sub.2 -antagonist that passes the blood brain barrier. Suitable H.sub.2 -antagonists include famotidine and ranitidine. The H.sub.2 -antagonists may be co-administered with other compounds such as histamine H,-antagonists which are known to be useful in the treatment of Parkinson's Disease, and can be formulated with such other compounds into a therapeutic composition.

## Claims

### Claim 1

A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, ranitidine, cimetidine, nizatidine, omeprazole, tiotidine, and aminofurazan compounds, that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.

### Claim 2

A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, ranitidine and cimetidine that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.

### Claim 3

A method for treating the symptoms of bradyphrenia in a patient suffering from Parkinson's Disease comprising administering to the patient a compound selected from the group consisting of famotidine, famotidine homologs and famotidine isomers that crosses the blood brain barrier in an amount effective to ameliorate the symptoms of bradyphrenia.

### Claim 4 (depends on 1, 2, 3)

A method according to claim 1, 2 or 3 wherein the compound is administered in an amount of from 20 to 600 mg/day.

### Claim 5 (depends on 4)

A method according to claim 4 wherein the compound is administered in an amount from 80 to 160 mg/day.

### Claim 6 (depends on 1, 2, 3)

A method according to claim 1, 2 or 3 wherein the compound is famotidine.

### Claim 7 (depends on 6)

A method according to claim 6, wherein the compound is administered in an amount of from 20 to 600 mg/day.

### Claim 8 (depends on 7)

A method according to claim 7 wherein the compound is administered in an amount of from 80 to 160 mg/day.

### Claim 9 (depends on 1, 2)

A method according to claim 1 or 2, wherein the compound is ranitidine.

### Claim 10 (depends on 1, 2, 3)

A method according to claim 1, 2 or 3 further comprising co-administering an additional therapeutic agent effective against symptoms of Parkinson's Disease other than bradyphrenia.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the additional therapeutic agent is a dopamine receptor agonist.

### Claim 12 (depends on 10)

A method according to claim 10, wherein the additional therapeutic agent is a histamine H.sub.1 -antagonist.

### Claim 13 (depends on 10)

A method according to claim 10, wherein the compound is famotidine.

### Claim 14 (depends on 10)

A method according to claim 10, wherein the compound is ranitidine.